BRCA testing in Asian ovarian cancer patients: Standard clinical practice or Mutation prediction model?
Journal
Cancer Epidemiology, Biomarkers & Prevention
Year
2026
Background
Germline BRCA1/2 testing is recommended for all patients with ovarian cancer, as identifying pathogenic variants (PV) informs treatment and enables family cascade testing. However, in resource-limited settings, high testing costs often limit feasibility. An alternative approach is to use predictive models to prioritize patients at risk, optimizing resource allocation. Existing models are largely Western-derived; in Asian populations, models exist for breast cancer—not ovarian cancer.
Materials & Methods
Using data from a multicenter study of 1,126 Asian patients with ovarian cancer (including 147 BRCA PV carriers), we developed models incorporating cancer history, clinicopathologic features, and reproductive factors to estimate the likelihood of carrying PVs. We assessed discrimination, calibration, and accuracy and compared genetic testing costs with a universal testing strategy.
Results
Our final model demonstrated good calibration and strong discriminatory power, with an area under the curve of 0.80 (95% confidence interval, 0.74–0.87). Factors included in the model were age at diagnosis, ethnicity, personal and family cancer history, and clinicopathologic features. The model had 77% accuracy at the optimal threshold for testing compared with 13% accuracy with universal testing, reducing genetic testing costs from ∼USD4,371 to ∼USD1,974 per identified carrier. Notably, while maintaining 100% sensitivity, the model reduced testing by 15%, yielding potential savings of ∼USD68,182 per 800 patients each year.
Conclusion
Targeted testing using a prediction model potentially offers a more efficient and scalable alternative when universal testing is not feasible, optimizing impact in resource-limited settings.
Resources and Links
Phone Number: +603 2781 4519 / +603 2781 4520
Share the Page
|
Information
Consultant Name
Dr Ahmad Radzi Ahmad Badruddin
For general questions about clinical trials
Phone Number: +603 2781 4519 / +603 2781 4520
Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.
In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.
If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you:
8, Jalan Bukit Pantai, 59100 Kuala Lumpur, Malaysia
.webp?sfvrsn=20763f7d_21)
.webp?sfvrsn=f2a2c343_12)
